title: Adalimumab-induced lupus erythematosus.
abstract: Adalimumab, an anti-tumour necrosis factor agent, especially used in the treatment of rheumatoid arthritis, has a good safety profile. One of the most common side-effects of adalimumab is the development of autoantibodies. Despite the induction of autoantibodies, the clinical presentation of immune-mediated complications upon adalimumab therapy, including a lupus-like syndrome, is very rare. We have recently evaluated a new case of adalimumab-induced lupus erythematosus.
authors.affiliation: Department of Dermatology, Hospital Clínico Universitario, Valencia, Spain. jmmart@eresmas.com
authors.forename: J M
authors.initials: JM
authors.lastname: Martín
authors.forename: J M
authors.initials: JM
authors.lastname: Ricart
authors.forename: J
authors.initials: J
authors.lastname: Alcácer
authors.forename: N
authors.initials: N
authors.lastname: Rausell
authors.forename: G
authors.initials: G
authors.lastname: Arana
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D012867:Skin / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D001323:Autoantibodies; D000068879:Adalimumab